Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1985-8-7
|
pubmed:abstractText |
The sensitivity of myeloid progenitor cells from normal subjects (N-CFU-GM) and from leukemic patients in complete remission (LR-CFU-GM) to 4-hydroperoxycyclophosphamide (4-HC) were compared to the sensitivity of leukemic progenitor cells (L-CFU) to this drug. The results were expressed as the dose of 4-HC needed to kill 90% (TD 90) of the progenitor cells. The mean TD 90 were respectively for N-CFU-GM : 59 (+/- 11 S.E.M.) nM ml-1 and for L-CFU 79 (+/- 6 S.E.M.) nM ml-1. Thus, L-CFU were equally sensitive to 4-HC as N-CFU-GM. Moreover, the mean TD 90 for LR-CFU-GM was 87 (+/- 5 S.E.M.) nM ml-1. Thus, the sensitivity of N-CFU-GM and LR-CFU-GM did not differ significantly from that of L-CFU. These results are not encouraging for the use of 4-HC in vitro to eliminate the residual leukemic cells from autologous bone marrow of AML patients in complete remission. The sensitivity of L-CFU was modified neither by previous cytoreductive therapy (different from cyclophosphamide) nor by the time elapsed since diagnosis of AML.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0145-2126
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
583-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3859709-Acute Disease,
pubmed-meshheading:3859709-Bone Marrow,
pubmed-meshheading:3859709-Cyclophosphamide,
pubmed-meshheading:3859709-Dose-Response Relationship, Drug,
pubmed-meshheading:3859709-Granulocytes,
pubmed-meshheading:3859709-Hematopoietic Stem Cells,
pubmed-meshheading:3859709-Humans,
pubmed-meshheading:3859709-Leukemia,
pubmed-meshheading:3859709-Leukemia, Myeloid, Acute,
pubmed-meshheading:3859709-Tumor Stem Cell Assay
|
pubmed:year |
1985
|
pubmed:articleTitle |
Effect of 4-hydroperoxycyclophosphamide on leukemic and normal human myeloid progenitor cells.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|